XML 35 R24.htm IDEA: XBRL DOCUMENT

SEGMENT INFORMATION (Tables)

9 Months Ended

Jun. 30, 2025

SEGMENT INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the three-month period ended June 30, 2025 is as follows:


		Therapeutic DNA			DNA Tagging and
		Production			Security Products			Consolidated
Revenues:
Product revenues		$	160,999		$	34,263		$	195,262
Service revenues			52,070			57,061			109,131
Less intersegment revenues			—			—			—
Total revenues		$	213,069		$	91,324		$	304,393

Gross profit		$	41,528		$	(36,398)		$	5,130

Segment operating expenses
Selling, general and administrative		$	1,074,583		$	119,770		$	1,194,353
Research and development			705,053			(42,909)			662,144
Total segment operating expenses		$	1,779,636		$	76,861		$	1,856,497
Loss from segment operations (a)		$	(1,738,108)		$	(113,259)		$	(1,851,367)

Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services and Kits			Security Products			Consolidated
Revenues:
Product revenues		$	218,858		$	—		$	27,786		$	246,644
Service revenues			59,901			—			166,244			226,145
Clinical laboratory service revenues			—			325,930			—			325,930
Less intersegment revenues			—			(1,200)			—			(1,200)
Total revenues			278,759			324,730			194,030			797,519

Gross profit			194,341			(12,260)			63,151			245,232

Segment operating expenses
Selling, general and administrative		$	852,919		$	165,983		$	604,955		$	1,623,857
Research and development			660,515			52,917			152,149			865,581
Total segment operating expenses		$	1,513,434		$	218,900		$	757,104		$	2,489,438
Loss from segment operations (a)		$	(1,319,093)		$	(231,160)		$	(693,953)		$	(2,244,206)

Information regarding operations by segment for the nine-month period ended June 30, 2025 is as follows:


		Therapeutic DNA			DNA Tagging and
		Production			Security Products			Consolidated
Revenues:
Product revenues		$	668,407		$	571,340		$	1,239,747
Service revenues			159,312			538,447			697,759
Clinical laboratory service revenues			—			—			—
Less intersegment revenues			—			—			—
Total revenues		$	827,719		$	1,109,787		$	1,937,506

Gross profit		$	428,187		$	578,700		$	1,006,887

Segment operating expenses
Selling, general and administrative		$	2,931,352		$	1,155,551		$	4,086,903
Research and development			2,146,426			138,293			2,284,719
Total segment operating expenses		$	5,077,778		$	1,293,844		$	6,371,622
(Loss) income from segment operations (a)		$	(4,649,591)		$	(715,144)		$	(5,364,735)

Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services and Kits			Security Products			Consolidated
Revenues:
Product revenues		$	477,010		$	—		$	470,076		$	947,086
Service revenues			202,635			—			476,142			678,777
Clinical laboratory service revenues			—			1,004,250			—			1,004,250
Less intersegment revenues			—			(11,800)			—			(11,800)
Total revenues		$	679,645		$	992,450		$	946,218		$	2,618,313

Gross profit		$	462,464		$	(56,703)		$	366,219		$	771,980

Segment operating expenses
Selling, general and administrative		$	2,371,501		$	771,499		$	1,758,312		$	4,901,312
Research and development			1,834,551			198,061			586,215			2,618,827
Total segment operating expenses		$	4,206,052		$	969,560		$	2,344,527		$	7,520,139
(Loss) income from segment operations (a)		$	(3,743,588)		$	(1,026,263)		$	(1,978,308)		$	(6,748,159)

(a)

Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

Schedule of reconciliation of segment loss from operations to corporate (loss) income

Reconciliation of loss from segment operations to Corporate (loss) income for the three-month periods ended June 30, 2025 and 2024 is as follows:


		June 30,
		2025			2024
Loss from operations of reportable segments		$	(1,851,367)		$	(2,244,206)
General corporate expenses (b)			(1,842,693)			(1,102,485)
Interest income			40,267			36,295
Unrealized gain on change in fair value of warrants classified as a liability			6,410			5,160,000
Net loss from discontinued operations			(336,195)			—
Other (expense) income, net			(531)			(103)
Consolidated net (loss) income		$	(3,984,109)		$	1,849,501

Reconciliation of loss from segment operations to Corporate loss for the nine-month periods ended June 30, 2025 and 2024 is as follows:


		June 30,
		2025			2024
Loss from operations of reportable segments		$	(5,364,735)		$	(6,748,159)
General corporate expenses (b)			(4,684,821)			(4,005,351)
Interest income			168,672			84,972
Unrealized gain on change in fair value of warrants classified as a liability			318,840			9,564,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification			—			(394,000)
Transaction costs allocated to warrant liabilities			—			(633,198)
Loss on issuance of warrants			—			(1,633,767)
Other (expense) income, net			(23,778)			(9,060)
Net loss from discontinued operations			(403,120)			—
Consolidated net loss		$	(9,988,942)		$	(3,774,563)

(b)

General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.